Anavex Life Sciences Corp. Common Stock (AVXL)

FairStock Score: 53/100 — MIXED

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

I approach this as a Graham-style exercise: what is proven by the numbers? Anavex is a 34-employee biopharmaceutical company developing CNS treatments, including blarcamesine. The filed figures show no revenue in fiscal 2025, 2024, or 2023, and net losses of $46.4 million, $43.0 million, and $47.5 million, respectively. The recent sequence is mixed: fiscal Q3 2026, the quarter ended 2026-06-30, produced net income of $7.8 million and diluted EPS of $0.08, but fiscal Q2 2026 lost $5.3 million and fiscal Q1 2026 lost $5.7 million. A single profitable quarter does not establish durable earning power. The competitive moat, if any, sits in clinical-stage drug candidates and intellectual property, not in current financial statements. There is no revenue to demonstrate pricing power, and trailing free cash flow was -$29.3 million, a -24.7% FCF yield on the $118.7 million market cap, both FairStock calculations. FairStock's P/E is -9.14, ROE -12.80%, ROCE -9.70%, and Piotroski F-Score 1/9; those are not the marks of a proven business. The Altman Z-Score of 6.25 is a relative balance-sheet positive in FairStock's calculation, but it does not offset ongoing losses. At the 2026-10-26 close of $1.28, P/B is 1.06, so the market is near stated book value; with no earnings, P/E is not meaningful. Growth is speculative until trials and filings convert into revenue. I would demand evidence of sustained profitability and cash generation before calling this cheap rather than merely early-stage.

In plain English: Anavex develops experimental medicines for brain and nerve diseases. In the figures shown, it has no reported revenue and has lost money in each full year, though one recent quarter showed a profit. At $1.28, it is hard to judge on profit because there is none; its market value is close to its accounting book value, so the price looks neither clearly cheap nor clearly expensive based on those numbers.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-26 close · note generated 2026-10-28 · model deepseek-flash

Sources (SEC EDGAR): fiscal Q3 2026 10-Q (period ended 2026-06-30) · fiscal Q2 2026 10-Q (period ended 2026-03-31) · fiscal Q1 2026 10-Q (period ended 2025-12-31) · fiscal Q3 2025 10-Q (period ended 2025-06-30) · FY2025 10-K/A (period ended 2025-09-30) · FY2024 10-K/A (period ended 2024-09-30) · FY2023 10-K/A (period ended 2023-09-30)

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer